Clearside Biomedical Names Charles Deignan Chief Financial Officer

Clearside Biomedical Names Charles Deignan Chief Financial Officer

10/29/2012 6:29:32 AM

ATLANTA---Clearside Biomedical Inc., an ophthalmic pharmaceutical company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, announced today that Charles Deignan has been named to the position of Chief Financial Officer. Deignan will report to Daniel White, President and CEO.

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.